Alexandra Balcom
CFO
Nuvalent, Inc.
Board Member
Crescent Biopharma, Inc. (CBIO)Equibles does not estimate personal net worth.
About Alexandra Balcom
Alexandra Balcom is recorded as CFO at Nuvalent, Inc. and Board Member at Crescent Biopharma, Inc. (CBIO). The newest filing on record that lists Alexandra Balcom as CFO at Nuvalent, Inc. is dated April 28, 2026. The newest filing on record that lists Alexandra Balcom as Board Member at Crescent Biopharma, Inc. (CBIO) is dated April 21, 2026. Crescent Biopharma, Inc. reported in an 8-K filed June 18, 2025 that Alexandra Balcom was appointed director, effective June 13, 2025. The proxy statement of Nuvalent, Inc. reports total compensation of $4,170,614 for Alexandra Balcom in fiscal 2025, including a base salary of $475,500. Disclosed compensation is on record for 4 fiscal years. Crescent Biopharma, Inc. is classified in the Biotechnology industry within the Healthcare sector. Nuvalent, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Crescent Biopharma, Inc. includes Joshua Brumm (CEO and Board Member), Peter Harwin (Chairman and Board Member), Richard Scalzo (CFO) and 7 others.
“On June 13, 2025, the Board decreased its size from eight to six members and appointed the following six individuals to the Board: Peter Harwin, Alexandra Balcom, Joshua Brumm, David Lubner, Susan Moran and Jonathan Violin.”
Affiliation history
-
Nuvalent, Inc.
CFO
Proxy statement
CurrentStart not stated–present
Last confirmed April 28, 2026
-
Current
Start not stated–present
Last confirmed April 21, 2026
Company network
Nuvalent, Inc.
Biotechnology · Healthcare
CFO
Leadership on record at Crescent Biopharma, Inc.
- Joshua Brumm CEO, Board Member
- Peter Harwin Chairman, Board Member
- Richard Scalzo CFO
- Rick Scalzo CFO
- Jonathan McNeill COO
- Barbara Bispham General Counsel
- Barbara Bispham Hale General Counsel
- Ryan Lynch Chief Accounting Officer
- David Lubner Board Member
- Jonathan Violin Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Nuvalent, Inc. | MBA, CPA Chief Financial Officer and Treasurer | $475,500 | $4,170,614 |
| 2024 | Nuvalent, Inc. | MBA, CPA Chief Financial Officer and Treasurer | $457,200 | $5,486,590 |
| 2023 | Nuvalent, Inc. | MBA, CPA Chief Financial Officer and Treasurer | $440,300 | $3,541,647 |
| 2022 | Nuvalent, Inc. | MBA, CPA Chief Financial Officer and Treasurer | $423,400 | $2,019,772 |